Testing a new lung cancer medication against standard chemotherapy

Plain-English translation of NCT04928846 on ClinicalTrials.gov ↗ · Source last updated September 2026 · Translation generated August 2026 · How we translate trials

What is this trial?

This is a clinical trial testing , a new investigational medication designed to treat advanced non-small cell lung cancer in patients who have already received prior treatment. The study will compare this medication to , a standard chemotherapy drug, to see which one works better at slowing or stopping cancer growth. Roughly 768 patients will be enrolled at about 330 hospitals and clinics worldwide.

Currently, patients with advanced lung cancer that has progressed despite previous treatments have limited options. Researchers believe this medication may offer better results with a different approach to targeting cancer cells, and this trial will determine whether it's more effective than the chemotherapy that is typically used next.

Do you qualify?

You likely qualify if…

you have been diagnosed with advanced non-small cell lung cancer that has a specific genetic marker called c-Met overexpression
your cancer has already been treated with at least one prior therapy and has progressed
you do not have an EGFR gene mutation (a specific type of genetic change)
you are well enough to participate in treatment and clinic visits, with a life expectancy of at least 12 weeks
your doctor believes you are appropriate for chemotherapy treatment
you have had a tumor sample tested to confirm your cancer meets the study's genetic requirements

You likely don't qualify if…

you have untreated or progressing cancer that has spread to your brain
you have cancer that has spread to the membrane surrounding your spinal cord or brain
your cancer is a type called adenosquamous or has neuroendocrine features
you have received more than one line of chemotherapy for your advanced cancer
you have certain other genetic mutations that require different standard treatments

What participation looks like

If you enroll, you'll be randomly assigned to receive either the new medication by IV infusion every 2 weeks or standard chemotherapy by IV infusion every 3 weeks. You'll continue treatment until your doctor determines it's no longer helping or side effects become too difficult. Throughout the trial, you'll attend regular clinic or hospital visits for blood tests, imaging scans to check how your cancer is responding, and assessments for any side effects—this may involve more visits than your usual care. If the treatment continues to help you, you may be eligible to keep receiving it after the formal trial ends.

Testing a new lung cancer medication against standard chemotherapy

What is this trial?

Do you qualify?

What participation looks like

Trial locations(317 sites)